NCT05956080

Brief Summary

Penicillin allergy testing among surgical patients

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2023

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 13, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 21, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

July 21, 2023

Status Verified

July 1, 2023

Enrollment Period

2 years

First QC Date

July 13, 2023

Last Update Submit

July 13, 2023

Conditions

Penicillin Allergy

Outcome Measures

Primary Outcomes (1)

  • Confirmed penicillin allergy

    1 week

Study Arms (1)

Allergy testing

OTHER
Diagnostic Test: Allergy testing

Interventions

Allergy testingDIAGNOSTIC_TEST

University Medicine Greifswald

Allergy testing

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • surgical patients with reported penicillin allergy

You may not qualify if:

  • missing consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Skin Tests

Intervention Hierarchy (Ancestors)

Immunologic TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesImmunologic Techniques

Study Officials

  • Sebastian Gibb, MD

    University Medicine Greifswald

    PRINCIPAL INVESTIGATOR

  • Christian S. Scheer, MD

    University Medicine Greifswald

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sebastian Gibb, MD

CONTACT

00493834 86 5801sebastian.gibb@med.uni-greifswald.de

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 13, 2023

First Posted

July 21, 2023

Study Start

September 1, 2023

Primary Completion

September 1, 2025

Study Completion

September 1, 2025

Last Updated

July 21, 2023

Record last verified: 2023-07